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Introduction
Granulomatosis with polyangiitis (Wegener's) (GPA) is a vascular disease characterized by granulomatous inflammation and systemic vasculitis predominantly in small vessels, commonly found in the respiratory tract [1] . Patients usually present local symptoms from the upper respiratory tract such as nasal crusting, sinusitis or nasal obstruction. ANCA prompt tissue damage via interactions with primed neutrophils and endothelial cells (EC)inducing diffuse endothelial dysfunction as reported in GPA [2] .
Angiotensin II (ANGII) is implicated in EC dysfunction and is the main effector of the reninangiotensin-aldosterone system (RAAS) with direct vascular effects. Apart from circulating ANGII there is also locally produced ANGII in the vascular endothelium. RAAS plays a major part in vasoconstriction [3, 4] , in hypertension and in tissue injury, and is regulated independently of circulating ANGII [5] . In vascular smooth muscle cells (VSMC), local ANGII may be more important than circulating ANGIIin vascular disorders [6] .ANGII blockage via angiotensin converting enzyme inhibitors (ACEI) or receptor inhibition is recommended for reduction of cardiovascular risk not only in atherosclerosis, but GPA as well. In this study, we have examined local ANGII expression, AT 1 R and AT 2 R in arteries from nasal biopsies with granulomatosis in patient with GPA using immunohistochemistry.
MATERIALS AND METHODS

Patients and Tissue collection
Nasal biopsy specimens from 16 patients were retrieved from archive at the Department of Pathology, (Helsingborg Hospital, Sweden). The original pathology reports were reviewed to verify the diagnosis GPA. The diagnosis was based on the American College of Rheumatology 1990 criteria for the classification of GPA [7] . Biopsies for nasal polyposis served as controls (n=8).The samples were handled in accordance with permit obtained from the regional Human Ethics Committee.
Immunohistochemistry
Sections were prepared as previously described [8] . 
Calculations and Statistics
The data were evaluated in a graded manner as non-parametric values and presented as the median and interquartile range. Exact values were presented counting the positive DAPI stained cells expressing immunostaining and presented with average values as parametric data. Group mean values were compared by non-parametric Mann-Whitney U test and average staining percentage as student t-test. Significance was defined as P <0.001 (***).
Values are presented as median or means ± standard error of the mean.
Results
Clinical and Hematoxylin-Eosin Staining
All subjects with GPA presented with symptoms from the respiratory tract at the time of biopsy. Foremost symptoms involved the nasal cavity (n=7) with nasal obstruction, purulent discharge or nasal crusting as well as otitis media. All patients had positive ANCA in conjunction with biopsy. The absence of granulomatous lesions in control samples from patients with nasal polyposis led to the classification of the sample as negative for GPA. All GPA patients had histopathology positive for granulomas and vasculitis (n=8) with inflammatory cells, including lymphocytes, histocytes and multinucleated giant cells (n=6).
Nasal biopsies from eight patients with GPA were compared with eight patients with clinical nasal polyposis.
ANGII Immunostaining
Immunostaining for ANGII was observed in the EC layer (Fig 1A and 1B) in arteries from control patients scoring +3 (average 69%±4%), all controls had positive staining (n=8). In the EC layer of the arteries from patients with GPA, there was no positive immunostaining in 38% of the patients (n=3). The median score was +1 (average 18,8%±6,3). Weak immunostaining of ANGII was observed in the smooth muscle cells in the vessel wall (Fig1A). Intra and extra arterial lymphocytes stained positively for ANGII both in control vessels and vessels with GPA.
AT 1 R Immunostaining
Immunostaining for AT 1 R was observed in the smooth muscle cell layer (n=8) (Fig 2A) and localized to the cytoplasm. The VSMC layer of the arteries from patients with GPA also stained positive for AT 1 R (Fig 2A) but the amount of positively stained VSMC differed markedly between the subjects and 38% (n=3) had no immunostaining. The GPA patients had a median score of +1 positive immunostaining (average15,6%±4,5) in the VSMC. Control patients had a median staining score of +4 (average 94%± 15) (p<0.001) (Fig 2B) . No immunostaining of AT 1 R was detected in the EC layer in arteries from control patients or patients with GPA. In the granulomatous lesions from patients with GPA, AT 1 R staining was observed in the lymphocytes (Fig 2A) .
AT 2 R Immunostaining
Immunostaining for AT 2 R was primarily located in the EC layer (Fig 3A) (100%, n=8) . Weak immunostaining was limited to the luminal part of the EC in healthy control subjects 100% (n=8). AT 2 R expression in the EC was only visualized in 38% (n=3) even with intact endothelium in patients with GPA. The GPA patients had a median score of 0 positive immunostaining (average 9,4%±4,5) in the VSMC. Control patients had a median staining score of +3 (average 69%± 3,5) (p<0.001) (Fig 3B) . Lymphocytes stained positively for AT 2 R in GPA and control patients.
Discussion
Major findings
The major findings in this study were a general reduction of ANGII immunostaining in the EC, AT 1 R downregulation in the VSMC together with reduced AT 2 R expression in the ECs in GPA subjects. ANGII, AT 1 R and AT 2 R immunostaining in inflammatory cells was vast.
ANGII receptors mediate the biologic effects via the AT 1 R and AT 2 R; these have been recognised and cloned in man [9] . AT 1 Rs are located on VSMC, while AT 2 Rs are found on EC.
Alternative pathways probably reduced AT 1 R expression in VSMC. Different growth factors, cytokines and hormones can either up or down regulate the AT 1 R expression [10] including C reactive protein (CRP) [11, 12] , exaggerating the pathological effects of AT 1 Rs.
The precise mechanisms prompting down regulation of ANGII and AT 1 R expression in patients with GPA cannot be deduced from this study. Apart from systemic ANGII, inflammatory mediators involved in the intense inflammatory reaction taking place in the granulomatous lesions may have contributed altering the AT 1 R and AT 2 R expression. Various molecules in the granuloma may modulate the AT 1 R expression in VSMC. Animal models as well as in vitro studies in humans have revealed that tumor necrosis factor-α (TNF-α) is involved in GPA [13] . Interleukin-1α (IL-1α), but not TNF-α or interferon-γ (IFN-γ), increases ANGII binding and AT 1 mRNA levels, whereas the combination of IL-1, TNF-, and IFN- decreases ANGII binding to VSMC [11] . In situations of intense systemic inflammation such as sepsis the combination of TNF- and other cytokines [10] contributes to a decrease in AT 1 R expression.
Our result shows a general downregulation of ANGII and the receptor subtypes. This down regulation of the angiotensin receptors were seen in VSMC or in the EC depending on the subtype of angiotensin receptor. Also ANGII is down regulated in the ECs in granulomatous lesions in GPA. The mechanisms altering ANGII or angiotensin receptors in vessels in GPA lesions cannot be concluded from the present study and the nature of this retrospective study did not allow for investigation of healthy vessels in GPA. 
